Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 351003-48-0 Chemical Structure| 351003-48-0

Structure of 351003-48-0

Chemical Structure| 351003-48-0

3-Chloro-2-fluorobenzenesulfonyl chloride

CAS No.: 351003-48-0

4.5 *For Research Use Only !

Cat. No.: A664620 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1g łÇʶÊÊ Inquiry Inquiry
5g łÇ˶ÊÊ Inquiry Inquiry
10g łË§¶ÊÊ Inquiry Inquiry
25g ł§î¶ÊÊ Inquiry Inquiry
100g łÇÍʶÊÊ Inquiry Inquiry
500g łÿòʶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 1g

    łÇʶÊÊ

  • 5g

    łÇ˶ÊÊ

  • 10g

    łË§¶ÊÊ

  • 25g

    ł§î¶ÊÊ

  • 100g

    łÇÍʶÊÊ

  • 500g

    łÿòʶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 351003-48-0 ]

CAS No. :351003-48-0
Formula : C6H3Cl2FO2S
M.W : 229.06
SMILES Code : O=S(C1=CC=CC(Cl)=C1F)(Cl)=O
MDL No. :MFCD03094234
InChI Key :LIRQNYQIFFLGIE-UHFFFAOYSA-N
Pubchem ID :2778321

Safety of [ 351003-48-0 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H314
Precautionary Statements:P280-P305+P351+P338-P310
Class:8
UN#:3265
Packing Group:

Computational Chemistry of [ 351003-48-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 12
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 3.0
Num. H-bond donors 0.0
Molar Refractivity 44.49
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

42.52 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.75
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.67
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

3.91
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.54
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.44
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.66

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.25
Solubility 0.13 mg/ml ; 0.000567 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.21
Solubility 0.14 mg/ml ; 0.00061 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.84
Solubility 0.033 mg/ml ; 0.000144 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.8 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.05

Application In Synthesis of [ 351003-48-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 351003-48-0 ]

[ 351003-48-0 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 351003-48-0 ]
  • 2-amino-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid methyl ester hydrochloride [ No CAS ]
  • [ 904679-63-6 ]
  • 2
  • [ 351003-48-0 ]
  • [ 870249-31-3 ]
  • C25H33ClFN3O3S [ No CAS ]
  • C25H33ClFN3O3S [ No CAS ]
  • 3
  • [ 351003-48-0 ]
  • 2-[3-chloro-2-(3-diethylamino-propylamino)-benzenesulfonylamino]-5,6,7,8-tetrahydro-naphthalene-1-carboxylic acid [ No CAS ]
YieldReaction ConditionsOperation in experiment
The following sulfonyl chlorides may be substituted for benzenesulfonyl chloride of Step One: ... 2-Chloro-4-fluorobenzenesulfonyl chloride 3-Chloro-4-fluorobenzenesulfonyl chloride 3-Chloro-2-fluorobenzenesulfonyl chloride 2-Chloro-6-methylbenzenesulfonyl chloride ...
  • 5
  • [ 351003-48-0 ]
  • [ 3306-62-5 ]
  • [ 1161943-96-9 ]
YieldReaction ConditionsOperation in experiment
19% With pyridine; for 12.0h; 2-Aminobenzenesulfonamide (54 mg, 0.31 mmol) and <strong>[351003-48-0]3-chloro-2-fluoro-benzenesulfonyl chloride</strong> (47 mg, 0.21 mmol) were dissolved in pyridine (1 ml) and the reaction mixture was stirred for 12 h. The solvent was removed in vacuo and the residue was purified by HPLC to give the product (15 mg, 19%).1H NMR (400 MHz, DMSO-d6) delta ppm 9.72 (br. s., 1H), 7.90 (t, 1H), 7.78-7.86 (m, 2H), 7.73 (br. s., 2H), 7.51-7.58 (m, 1H), 7.46-7.51 (m, 1H), 7.39 (t, 1H), 7.26-7.34 (m, 1H);MS m/z M-H 363.
  • 6
  • [ 351003-48-0 ]
  • [ 2930-05-4 ]
  • [ 100-46-9 ]
  • [ 1215721-21-3 ]
  • 7
  • [ 351003-48-0 ]
  • [ 1015170-94-1 ]
  • [ 1015168-91-8 ]
  • 10
  • [ 351003-48-0 ]
  • [ 100202-39-9 ]
  • [ 1392442-35-1 ]
  • 11
  • [ 351003-48-0 ]
  • 2C2HF3O2*C13H18N4O [ No CAS ]
  • [ 1392441-83-6 ]
  • 12
  • [ 351003-48-0 ]
  • [ 1380228-73-8 ]
  • [ 1380229-08-2 ]
YieldReaction ConditionsOperation in experiment
With pyridine; In dichloromethane; at 50℃; for 2.0h; The 2,6-difluoro-N1-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-yl)benzene-1,3-diamine(20 mg, 0.047 mmol) prepared at Step 9 was added and dissolved into dichloromethane solvent. <strong>[351003-48-0]3-chloro-2-fluorobenzene-1-sulfonyl chloride</strong> (16 mg, 0.07 mmol) and pyridine (8 uL, 0.094 mmol) were added into the reaction solution and stirred at 50C for 2 hours. After the reaction, the reactant was washed with 1N aqueous hydrochloric acid solution and salt water. After extraction with dichloromethane, the organic layer was dried with sulfuric anhydride magnesium and vacuum concentrated, and then refined by means of column chromatography, so that the target compound was obtained.1H NMR(400MHz, CDCl3): delta 11. 55 (s, 1H), 9.63(m, 1H), 8.99(d, J = 6.0 Hz, 1H), 8.39(d, J = 6.0 Hz, 1H), 8.20(s, 1H), 7.72(m, 1H), 7.61(m, 1H), 7.30(m, 1H), 7.18(m, 1H), 6.94(m, 2H), 5.91(m, 1H), 4.23(d, J = 11.2 Hz, 1H), 3.85(m, 1H), 2.19-1.72(m, 6H).
  • 13
  • [ 351003-48-0 ]
  • [ 351003-58-2 ]
  • 14
  • [ 351003-48-0 ]
  • [ 1204573-07-8 ]
  • 15
  • [ 351003-48-0 ]
  • [ 1204573-08-9 ]
  • 16
  • [ 351003-48-0 ]
  • [ 1204573-06-7 ]
  • 17
  • [ 2106-04-9 ]
  • [ 351003-48-0 ]
  • 18
  • [ 351003-48-0 ]
  • tert-butyl 6-(4-aminophenyl)-3-[bis(tert-butoxycarbonyl)amino]indazole-1-carboxylate [ No CAS ]
  • C34H38ClFN4O8S [ No CAS ]
  • 19
  • [ 351003-48-0 ]
  • [ 535170-20-8 ]
  • C17H16ClF3N2O4S [ No CAS ]
  • 20
  • [ 351003-48-0 ]
  • C13H20N2O2 [ No CAS ]
  • (R)-3-chloro-2-fluoro-N-{1-[2-(2-methoxyphenoxy)ethyl]pyrrolidin-3-yl}benzenesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
78% With triethylamine; In dichloromethane; at 0℃; A mixture of the appropriate deprotected amine (0.38 mmol) in CH2Cl2 (3 mL), and TEA (1.14 mmol) was cooled down (ice bath), and arylsulfonyl chloride (1.37 mmol) was added at 0 C in one portion. The reaction mixture was stirred for 2-6 h under cooling. Then, the solvent was evaporated and the sulfonamides were purified using silica gel column with CH2Cl2/MeOH (9:0.7 v/v) as an eluting system. Compound 24, which evaluated in in vivo testes was further converted into the hydrochloride salts by treatment of their solution in anhydrous ethanol with 1.25 M HCl in MeOH.
  • 21
  • [ 351003-48-0 ]
  • C13H20N2O2 [ No CAS ]
  • (S)-3-chloro-2-fluoro-N-{1-[2-(2-methoxyphenoxy)ethyl]pyrrolidin-3-yl}benzenesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
80% With triethylamine; In dichloromethane; at 0℃; General procedure: A mixture of the appropriate deprotected amine (0.38 mmol) in CH2Cl2 (3 mL), and TEA (1.14 mmol) was cooled down (ice bath), and arylsulfonyl chloride (1.37 mmol) was added at 0 C in one portion. The reaction mixture was stirred for 2-6 h under cooling. Then, the solvent was evaporated and the sulfonamides were purified using silica gel column with CH2Cl2/MeOH (9:0.7 v/v) as an eluting system. Compound 24, which evaluated in in vivo testes was further converted into the hydrochloride salts by treatment of their solution in anhydrous ethanol with 1.25 M HCl in MeOH.
  • 22
  • [ 351003-48-0 ]
  • C15H24N2O2 [ No CAS ]
  • (R)-3-chloro-2-fluoro-N-{1-[2-(2-isopropoxyphenoxy)ethyl]pyrrolidin-3-yl}benzenesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
71% With triethylamine; In dichloromethane; at 0℃; General procedure: A mixture of the appropriate deprotected amine (0.38 mmol) in CH2Cl2 (3 mL), and TEA (1.14 mmol) was cooled down (ice bath), and arylsulfonyl chloride (1.37 mmol) was added at 0 C in one portion. The reaction mixture was stirred for 2-6 h under cooling. Then, the solvent was evaporated and the sulfonamides were purified using silica gel column with CH2Cl2/MeOH (9:0.7 v/v) as an eluting system. Compound 24, which evaluated in in vivo testes was further converted into the hydrochloride salts by treatment of their solution in anhydrous ethanol with 1.25 M HCl in MeOH.
  • 23
  • [ 351003-48-0 ]
  • C15H24N2O2 [ No CAS ]
  • (S)-3-chloro-2-fluoro-N-{1-[2-(2-isopropoxyphenoxy)ethyl]pyrrolidin-3-yl}benzenesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
75% With triethylamine; In dichloromethane; at 0℃; General procedure: A mixture of the appropriate deprotected amine (0.38 mmol) in CH2Cl2 (3 mL), and TEA (1.14 mmol) was cooled down (ice bath), and arylsulfonyl chloride (1.37 mmol) was added at 0 C in one portion. The reaction mixture was stirred for 2-6 h under cooling. Then, the solvent was evaporated and the sulfonamides were purified using silica gel column with CH2Cl2/MeOH (9:0.7 v/v) as an eluting system. Compound 24, which evaluated in in vivo testes was further converted into the hydrochloride salts by treatment of their solution in anhydrous ethanol with 1.25 M HCl in MeOH.
  • 24
  • [ 351003-48-0 ]
  • C16H26N2O2 [ No CAS ]
  • 3-chloro-2-fluoro-N-{1-[2-(2-isopropoxyphenoxy)ethyl]piperidin-4-yl}benzenesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
77% With triethylamine; In dichloromethane; at 0℃; General procedure: A mixture of the appropriate deprotected amine (0.38 mmol) in CH2Cl2 (3 mL), and TEA (1.14 mmol) was cooled down (ice bath), and arylsulfonyl chloride (1.37 mmol) was added at 0 C in one portion. The reaction mixture was stirred for 2-6 h under cooling. Then, the solvent was evaporated and the sulfonamides were purified using silica gel column with CH2Cl2/MeOH (9:0.7 v/v) as an eluting system. Compound 24, which evaluated in in vivo testes was further converted into the hydrochloride salts by treatment of their solution in anhydrous ethanol with 1.25 M HCl in MeOH.
  • 25
  • [ 351003-48-0 ]
  • C15H24N2O2 [ No CAS ]
  • 3-chloro-2-fluoro-N-[1-(2-(2-methoxyphenoxy)ethyl)piperidin-4-yl]methyl}benzenesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
65% With triethylamine; In dichloromethane; at 0℃; General procedure: A mixture of the appropriate deprotected amine (0.38 mmol) in CH2Cl2 (3 mL), and TEA (1.14 mmol) was cooled down (ice bath), and arylsulfonyl chloride (1.37 mmol) was added at 0 C in one portion. The reaction mixture was stirred for 2-6 h under cooling. Then, the solvent was evaporated and the sulfonamides were purified using silica gel column with CH2Cl2/MeOH (9:0.7 v/v) as an eluting system. Compound 24, which evaluated in in vivo testes was further converted into the hydrochloride salts by treatment of their solution in anhydrous ethanol with 1.25 M HCl in MeOH.
  • 26
  • [ 351003-48-0 ]
  • C17H28N2O2 [ No CAS ]
  • 3-chloro-2-fluoro-N-[1-(2-(2-isopropoxyphenoxy)ethyl)piperidin-4-yl]methyl}benzenesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
79% With triethylamine; In dichloromethane; at 0℃; General procedure: A mixture of the appropriate deprotected amine (0.38 mmol) in CH2Cl2 (3 mL), and TEA (1.14 mmol) was cooled down (ice bath), and arylsulfonyl chloride (1.37 mmol) was added at 0 C in one portion. The reaction mixture was stirred for 2-6 h under cooling. Then, the solvent was evaporated and the sulfonamides were purified using silica gel column with CH2Cl2/MeOH (9:0.7 v/v) as an eluting system. Compound 24, which evaluated in in vivo testes was further converted into the hydrochloride salts by treatment of their solution in anhydrous ethanol with 1.25 M HCl in MeOH.
  • 27
  • [ 351003-48-0 ]
  • [ 1567836-37-6 ]
  • [ 1567836-55-8 ]
YieldReaction ConditionsOperation in experiment
63% With pyridine; In dichloromethane; at 20 - 45℃;Inert atmosphere; General procedure: To a solution of 76 (120 mg, 0.37 mmol) in dry pyridine (12 mL) under N2 at RT, was added 2,4-difluorobenzenesulphonyl chloride (159 mg, 0.74 mmol) in CH2Cl2 (1.5 mL) dropwise over 5 min. The mixture was stirred at 45 C under N2 for 16 , and the solvent then removed under reduced pressure. The reaction was quenched with a little water and the resulting solid collected by filtration and washed with water and Et2O. Purification was carried out by trituration with hot CH2Cl2/MeOH solution to give 4 as a pale brown solid (65%).
  • 28
  • [ 351003-48-0 ]
  • ethyl (S)-3-allyl-6-chloro-7-fluoro-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide [ No CAS ]
  • 29
  • [ 351003-48-0 ]
  • C10H7ClFNO4S [ No CAS ]
  • 30
  • [ 351003-48-0 ]
  • C14H17ClFNO5S [ No CAS ]
  • 31
  • [ 351003-48-0 ]
  • [ 75-64-9 ]
  • C10H13ClFNO2S [ No CAS ]
  • 32
  • [ 351003-48-0 ]
  • [ 105807-83-8 ]
  • 3-chloro-N-(2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-2-fluorobenzenesulfonamide [ No CAS ]
  • 33
  • [ 351003-48-0 ]
  • 3-amino-9-oxo-9H-xanthene-1,8-diyl bis(2,2-dimethylpropanoate) [ No CAS ]
  • C29H27ClFNO8S [ No CAS ]
YieldReaction ConditionsOperation in experiment
With pyridine; at 20℃; General procedure: To a solution of amine 7 (41 mg, 0.1 mmol) indry pyridine (2 mL), substituted benzenesulfonyl chloride (1.52 eq.) was added. The reaction mixturewas kept at r.t. overnight and poured into a mixture of 1 M hydrochloric acid (10 mL) and ethyl acetate(10 mL) while being vigorously stirred. The organic phase was separated and concentrated in vacuo.The residue was dissolved in a mixture of methanol (10 mL) and 5 M sodium hydroxide solution(5 mL) and kept at r.t. for 1 h. The mixture was concentrated in vacuo to remove the methanol andwas diluted with water (3 mL) and ltered. The clear water phase was washed with ethyl acetate(3 mL x 2) and then concentrated hydrochloric acid was added dropwise until pH = 4. The mixturewas filtered to afford the desired sulfonamide 9a-9n as yellow solids (yield: 30-80%).
  • 34
  • [ 351003-48-0 ]
  • tert-butyl ((1-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)piperidin-4-yl)methyl)carbamate [ No CAS ]
  • 3-chloro-2-fluoro-N-[(1-{2-[(2,2,2-trifluoroethoxy)phenoxy]ethyl}piperidin-4-yl)methyl]benzenesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
82% General procedure: Intermediates 5-7 were converted into their TFA salts by treatment with a mixture of TFA/CH2Cl2(4 mL/1 mL). The excess reagent and solvent were removed under reduced pressure and maintainedovernight under vacuum. A mixture of the appropriate (aryloxy)ethyl alicyclic amine (1 eq) in CH2Cl2(3 mL) and TEA (3 eq) was then cooled in an ice bath, and the proper arylsulfonyl chloride (1.2 eq)was added at 0 C (the entire amount was added at the same time). The reaction mixture was stirredfor 2-6 h under cooling. The solvent was evaporated, and the sulfonamides were a purified silica-gelcolumn with CH2Cl2/MeOH (9/0.7, v/v) as an eluting system (isolated yields 55-87%). Compounds 9and 10, selected for in vivo pharmacological evaluation, were further converted into the hydrochloridesalts by treatment of their solution in anhydrous ethanol with 1.25 M HCl in MeOH.
  • 35
  • [ 351003-48-0 ]
  • C12H10N2O [ No CAS ]
  • 3-chloro-2-fluoro-N-(1-methyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzenesulfonamide [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 351003-48-0 ]

Fluorinated Building Blocks

Chemical Structure| 13656-57-0

A685021 [13656-57-0]

5-Chloro-2,4-difluorobenzenesulfonylchloride

Similarity: 0.97

Chemical Structure| 351003-49-1

A292472 [351003-49-1]

5-Chloro-2-fluorobenzenesulfonyl chloride

Similarity: 0.94

Chemical Structure| 2905-21-7

A266144 [2905-21-7]

2-Fluorobenzene-1-sulfonyl chloride

Similarity: 0.84

Chemical Structure| 13918-92-8

A684027 [13918-92-8]

2,4-Difluorobenzene-1-sulfonyl chloride

Similarity: 0.83

Chemical Structure| 26120-86-5

A642197 [26120-86-5]

2,5-Difluorobenzene-1-sulfonyl chloride

Similarity: 0.83

Aryls

Chemical Structure| 13656-57-0

A685021 [13656-57-0]

5-Chloro-2,4-difluorobenzenesulfonylchloride

Similarity: 0.97

Chemical Structure| 351003-49-1

A292472 [351003-49-1]

5-Chloro-2-fluorobenzenesulfonyl chloride

Similarity: 0.94

Chemical Structure| 2905-21-7

A266144 [2905-21-7]

2-Fluorobenzene-1-sulfonyl chloride

Similarity: 0.84

Chemical Structure| 13918-92-8

A684027 [13918-92-8]

2,4-Difluorobenzene-1-sulfonyl chloride

Similarity: 0.83

Chemical Structure| 26120-86-5

A642197 [26120-86-5]

2,5-Difluorobenzene-1-sulfonyl chloride

Similarity: 0.83

Sulfonyl Chlorides

Chemical Structure| 13656-57-0

A685021 [13656-57-0]

5-Chloro-2,4-difluorobenzenesulfonylchloride

Similarity: 0.97

Chemical Structure| 351003-49-1

A292472 [351003-49-1]

5-Chloro-2-fluorobenzenesulfonyl chloride

Similarity: 0.94

Chemical Structure| 2905-21-7

A266144 [2905-21-7]

2-Fluorobenzene-1-sulfonyl chloride

Similarity: 0.84

Chemical Structure| 26120-86-5

A642197 [26120-86-5]

2,5-Difluorobenzene-1-sulfonyl chloride

Similarity: 0.83

Chemical Structure| 1208075-41-5

A581212 [1208075-41-5]

4-Bromo-5-chloro-2-fluorobenzene-1-sulfonyl chloride

Similarity: 0.78

Chlorides

Chemical Structure| 13656-57-0

A685021 [13656-57-0]

5-Chloro-2,4-difluorobenzenesulfonylchloride

Similarity: 0.97

Chemical Structure| 351003-49-1

A292472 [351003-49-1]

5-Chloro-2-fluorobenzenesulfonyl chloride

Similarity: 0.94

Chemical Structure| 2905-21-7

A266144 [2905-21-7]

2-Fluorobenzene-1-sulfonyl chloride

Similarity: 0.84

Chemical Structure| 13918-92-8

A684027 [13918-92-8]

2,4-Difluorobenzene-1-sulfonyl chloride

Similarity: 0.83

Chemical Structure| 26120-86-5

A642197 [26120-86-5]

2,5-Difluorobenzene-1-sulfonyl chloride

Similarity: 0.83